IMMUNO Division of BAXTER, Biomedical Research Center, Uferstrasse 15, 2304, Orth/Donau, Austria.
Cytotechnology. 1999 Jul;30(1-3):1-16. doi: 10.1023/A:1008030407679.
Coagulation factors, amongst many other proteins, often require posttranslational endoproteolytic processing for maturation. Upon high yield expression of recombinant forms of these proteins, processing frequently becomes severely limiting, resulting in a hampered function of the protein. In this report, the human endoprotease Furin was used to achieve complete propeptide removal from recombinant von Willebrand Factor (rvWF) precursors in CHO cells. At expression beyond 200 ng rvWF/106 cells x day, processing became insufficient. Stable co- and overexpression of full length Furin resulted in complete precursor cleavage in cell clones expressing 2 mug rvWF/106 cells x day. Rather than occuring intracellularly, processing was found to be mediated by a naturally secreted form of rFurin, present in 100 fold higher concentrations than endogenous Furin and accumulating in the cell culture supernatant. Attempts to increase rFurin yield by amplification, in order to ensure complete rvWF precursor processing at expression rates beyond 2 mug rvWF/106 cells x day, failed. Truncation of the trans-membrane domain resulted in immediate secretion of rFurin and approximately 10 fold higher concentrations in the conditioned medium. In cases where these high rFurin concentrations are not sufficient to ensure complete processing, an in vitro downstream processing procedure has to be established. Secreted affinity epitope-tagged rFurin derivatives were constructed, the fate of which, at expression, was dependent on the size of the C-terminal truncation and the type of the heterologous epitope added. A suitable candidate was purified by a one step affinity procedure, and successfully used for in vitro processing. This allows complete proteolytic processing of large amounts of precursor molecules by comparably small quantities of rFurin. Complete precursor cleavage of a target protein at expression rates of up to approximately 200 ng, 2 mug, and 20 mug, as well as beyond 20 mug/106 cells x day can thus be anticipated to be accomplished by endogenous Furin, additional expression of full length rFurin, co-expression of truncated and hence secreted rFurin, and a protein-chemical in vitro procedure, respectively.
凝血因子和许多其他蛋白质一样,通常需要翻译后内切蛋白酶处理才能成熟。在重组形式的这些蛋白质的高产表达时,处理经常变得严重受限,导致蛋白质的功能受阻。在本报告中,使用人内切蛋白酶弗林(Furin)在 CHO 细胞中完成重组血管性血友病因子(rvWF)前体的完整前肽去除。在超过 200ng rvWF/106 细胞 x 天的表达时,处理变得不足。全长弗林的稳定共表达和过表达导致在表达 2μg rvWF/106 细胞 x 天的细胞克隆中完全切割前体。加工不是在细胞内发生,而是通过一种自然分泌的 rFurin 形式介导的,这种形式的 rFurin 存在于 100 倍于内源性 Furin 的浓度,并在细胞培养上清液中积累。为了确保在超过 2μg rvWF/106 细胞 x 天的表达率下完全加工 rvWF 前体,尝试通过扩增增加 rFurin 的产量,但失败了。跨膜结构域的截断导致 rFurin 的立即分泌和在条件培养基中的浓度约增加 10 倍。在这些高浓度的 rFurin 不足以确保完全加工的情况下,必须建立体外下游加工程序。构建了分泌的亲和表位标记的 rFurin 衍生物,其表达时的命运取决于 C 端截断的大小和添加的异源表位的类型。一种合适的候选物通过一步亲和程序进行纯化,并成功用于体外处理。这使得大量前体分子可以通过相对少量的 rFurin 进行完全蛋白水解加工。因此,预计靶蛋白的完全前体切割可以通过内源性 Furin、全长 rFurin 的额外表达、截断和因此分泌的 rFurin 的共表达以及蛋白质化学的体外程序来完成,分别在高达约 200ng、2μg 和 20μg 的表达率,以及超过 20μg/106 细胞 x 天。